Resources: Get Active Home
Resources: Recipes Your health
Resources: 'Meet Your Meat' 'Vegetarian 101
Resources: Take the 30-Day Veg Pledge Amazing Animals
Resources: Famous Vegetarians Cruelty to Animals
Resources: Books and Web Sites The Environment
Resources: Literature and Merchandise

Nutrition

Resources: In the News World Hunger
 

USING MODERN WEIGHT-LOSS DRUGS: SIBUTRAMINE AND ORLISTAT

Studies with sibutramine and orlistat in a clinical setting have been designed to show what happens in 'real life'. Results from both are favourable, and indeed broadly comparable. On average, one can expect weight loss of around 9% maintained over 12 months, among those who respond to, and continue treatment. However, while every physician involved in weight management will be able to tell you of the marvelously successful patient who lost 40% body weight, they will equally be able to tell you of their abject failures.

Sibutramine

When used in conjunction with a low-calorie diet, data show that 77% of sibutramine-administered patients achieve a medically beneficial weight loss of at least 5%. Importantly, continuation of therapy can sustain these weight losses for at least 2 years. Further, a recent meta-analysis has shown that, in sibutramine-administered obese patients, subjects who achieved weight losses of over 4 kg in the first 3 months of treatment were more likely to achieve long-term weight loss maintenance if therapy was continued. This in turn, led to marked improvements in metabolic factors such as lipid profile, insulin sensitivity and hypertension.

Orlistat

A placebo-controlled study involving obese patients found that orlistat can promote and maintain weight loss (when administered in conjunction with a hypocaloric and a eucaloric diet, respectively). During the weight-loss phase (year 1), orlistat patients lost 10.2% body weight, compared with 6.1% in the placebo group. Results from the weight-maintenance phase of the trial (year 2) showed that patients who continued on orlistat regained half as much weight as patients switched to placebo. Weight-loss-associated improvements in cardiovascular risk factors, including lipid profile, blood pressure and fasting glucose, have also been demonstrated.

*49/312/5*

WEIGHT LOSS/BODY-BUILDING

 

THE HORMONAL CONNECTION: THE ADRENAL GLANDS - DIAGNOSIS
ROTATION DIET AND BUILDING CONFIDENCE: A NOTE ON JUNK FOOD
'WEIGHT DOWN AND THE DESERT OF TESTING: THE MATTHEW 19:29 PRINCIPLE
IMMUNE POWER DIET: THE MINERAL IQ QUIZ
BREAKING BAD HABITS
SMART DRUGS
CONSCIOUS COMBINING EXPLAINED: TO VITAMIN OR NOT TO VITAMIN?
WEIGHT PROBLEMS: ADULTS AND CHILDREN
USING MODERN WEIGHT-LOSS DRUGS: SIBUTRAMINE AND ORLISTAT
BLOOD SUGAR AND THE HIGH CARBOHVARATE DIET: TAMING INSULIN'S INTENSITY